{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-026236","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2022-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.293278+00:00","generated_at":"2026-06-21T07:23:04.558820+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"KalVista terminates KVD824 Phase 2 trial over liver enzyme elevations; net loss widens to $22.3M","bullets":["Phase 2 KOMPLETE trial for KVD824 terminated due to patient liver enzyme elevations; future development uncertain.","Net loss of $22.3M ($0.90 per share) for quarter ended Oct 31, 2022 vs $19.7M ($0.80) a year ago.","Cash, cash equivalents and marketable securities at $122.3M as of Oct 31, 2022, down from $166.2M at Apr 30.","Phase 3 KONFIDENT trial for sebetralstat on track; data expected H2 2023, NDA filing planned H1 2024.","Appointed Brian J. G. Pereira, M.D., as Chairman of the Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-026236","json":"https://secwatch.observer/filing/0000950170-22-026236.json","markdown":"https://secwatch.observer/filing/0000950170-22-026236.md","text":"https://secwatch.observer/filing/0000950170-22-026236.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000095017022026236/0000950170-22-026236-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000095017022026236/kalv-20221208.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T07:23:04.558820+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7f5d08b44680ab0fe7451713fcb678920e301321","claim":"KalVista Pharmaceuticals, Inc. reported second fiscal quarter ended October 31, 2022 results: net income $22.3 million, EPS $(0.90) per weighted average basic and diluted share.","evidence_excerpt":"Net loss was $22.3 million, or $(0.90) per weighted average basic and diluted share, for the three months ended October 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000095017022026236/0000950170-22-026236-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second fiscal quarter ended October 31, 2022"},{"label":"Net income","value":"$22.3 million"},{"label":"EPS","value":"$(0.90) per weighted average basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}